{"id":781242,"date":"2023-08-31T07:09:42","date_gmt":"2023-08-31T11:09:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/"},"modified":"2023-08-31T07:09:42","modified_gmt":"2023-08-31T11:09:42","slug":"alx-oncology-announces-september-investor-conference-participation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/","title":{"rendered":"ALX Oncology Announces September Investor Conference Participation"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.<\/p>\n<p align=\"justify\">\n        <strong>H.C. Wainwright 25<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Investment Conference<\/strong><br \/>\n        <br \/>Format: Fireside chat with analyst, Swayampakula Ramakanth <br \/>Date: Monday, September 11<br \/>Time: 2:30 PM Eastern Time<br \/>Location: New York, NY <br \/>Webcast link: Available\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZpQz0KMJszADINAMkjZkeLtw0SDlAoFz8qS4ZVcBX5kt-JZ5Y5EoejkGQrWPYS3vZl2Ulo9JHN6TlrZNDNpVSXsqHVMr6QIKc_fUAF4GoNeIX3cn54CaTt5PF2Te8ZTN\" rel=\"nofollow noopener\" target=\"_blank\"><u>here<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>2023 Cantor Global Healthcare Conference<\/strong><br \/>\n        <br \/>Format: Fireside chat with analyst, Li Watsek<br \/>Date: Tuesday, September 26<br \/>Time: 9:10 AM Eastern Time<br \/>Location: New York, NY <br \/>Webcast link: Available\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZpQz0KMJszADINAMkjZkeIPXH-Ru6EDantYK4ZFHJ9KG4lOLCfwjkfh9pJdR_5migwwzt2nXH4N8qIGPFGll-xO0F9fl1dgK_H4Sw6_SX8c=\" rel=\"nofollow noopener\" target=\"_blank\"><u>here<\/u><\/a><\/p>\n<p align=\"justify\">The live webcasts for the H.C. Wainwright and Cantor fireside chats can be accessed by visiting the Investors section of ALX Oncology\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rJYB7S4u7oDKwJarN55QRiGxqtgGukiZA9IsZrth39FbOESic8N4OtjKIsV8lu1KpLhlL2TbH2kT-9-6T5G9jYMbXICL-R7p2Sa41d5kTlQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.alxoncology.com<\/a> and selecting\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8RIro6LnRMbbXHa4i-iiHhF8m28vkQ2u4AgKjHh2K6w4U-fyHMfp_Hfpu-tskv6r1zZL5_UbuIGTw80PTGjSLiugfoW8LIsxzUzt6C-j__0CS-yX3dPSefgtFdprmfQVO8sEBLYunBHk6yO0b5SrUt4fehB5aSmCSo6SLdS2MpSkVpnkFrUhIZ2wDPt6zEe0ioVF0gEDdf1ozPM3zuam_uM-3aXPS-cMsNrNAef6nGaLTEmd0iFBcL5UpmYKw_uPfSTQJvcQKAlDJN2q6Z-hOQ==\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a>\u00a0under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.<\/p>\n<p align=\"justify\">\n        <strong>About ALX Oncology<\/strong>\n      <\/p>\n<p align=\"justify\">ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology\u2019s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies (ADCs), and PD-1\/PD-L1 immune checkpoint inhibitors.<\/p>\n<p align=\"justify\">\n        <strong>Evorpacept\u2019s Rational Design and Dual Development Pillars<\/strong>\n      <\/p>\n<p align=\"justify\">Rationally engineered with an inactive Fc effector function, evorpacept\u2019s clinical data to date has demonstrated a substantially improved safety profile over other anti-CD47 molecules in the clinic with an active Fc (i.e., binding the Fc gamma receptor on macrophages). This superior safety profile allows higher dosing with minimal overlapping toxicity in the combination treatment setting. CD47 expressed on cancer cells binds to its receptor SIRP alpha, which is predominantly expressed on two cell types: macrophages and dendritic cells. ALX Oncology is focusing evorpacept development with the standard-of-care agents as originally designed revolving around these two cell types, including:<\/p>\n<p align=\"justify\">\n        <strong>Anti-cancer antibodies (the \u201c<\/strong><br \/>\n        <em>don\u2019t eat me<\/em><br \/>\n        <strong>\u201d signal):<\/strong>\u00a0evorpacept enables Fc-mediated antibody-dependent phagocytosis by macrophages in combination with anti-cancer antibodies (e.g., Herceptin\u00ae) with an active Fc domain, which is otherwise impaired by CD47 expression on cancer cells binding to SIRP alpha on macrophages. This same mechanism of action applies to ADCs.<\/p>\n<p align=\"justify\">\n        <strong>PD-1\/PD-L1 immune checkpoint inhibitors (the \u201c<\/strong><br \/>\n        <em>don\u2019t activate T-cells<\/em><br \/>\n        <strong>\u201d signal)<\/strong>: evorpacept enables T-cell activation by dendritic cells that are constitutively inhibited by CD47 expression on cancer cells binding to SIRP alpha on dendritic cells. Activated dendritic cells present neoantigens to T-cells that once activated will kill cancer cells when the PD-1\/PD-L1 inhibitory interaction is blocked by T-cell checkpoint inhibitors.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTNkZjgwYWMtZGYzZS00MTk5LWI5Y2QtNmNiZjZmMjhkYjY1LTEyMDQ0MTY=\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contacts:\r\n\r\nPeter Garcia\r\nChief Financial Officer, ALX Oncology\r\n(650) 466-7125 Ext. 113\r\npeter@alxoncology.com\r\n\r\nMalini Chatterjee, Ph.D.\r\nBlueprint Life Science Group\r\nmchatterjee@bplifescience.com\r\n\r\nMedia Contact:\r\n\r\nKaren Sharma\r\nMacDougall\r\n(781) 235-3060\r\nalx@macbiocom.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference Format: Fireside chat with analyst, Swayampakula Ramakanth Date: Monday, September 11Time: 2:30 PM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here 2023 Cantor Global Healthcare Conference Format: Fireside chat with analyst, Li WatsekDate: Tuesday, September 26Time: 9:10 AM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here The live webcasts for the H.C. Wainwright and Cantor fireside chats can be accessed by visiting the Investors section of ALX Oncology\u2019s website at www.alxoncology.com &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology Announces September Investor Conference Participation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781242","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology Announces September Investor Conference Participation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology Announces September Investor Conference Participation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference Format: Fireside chat with analyst, Swayampakula Ramakanth Date: Monday, September 11Time: 2:30 PM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here 2023 Cantor Global Healthcare Conference Format: Fireside chat with analyst, Li WatsekDate: Tuesday, September 26Time: 9:10 AM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here The live webcasts for the H.C. Wainwright and Cantor fireside chats can be accessed by visiting the Investors section of ALX Oncology\u2019s website at www.alxoncology.com &hellip; Continue reading &quot;ALX Oncology Announces September Investor Conference Participation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T11:09:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology Announces September Investor Conference Participation\",\"datePublished\":\"2023-08-31T11:09:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/\"},\"wordCount\":479,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/\",\"name\":\"ALX Oncology Announces September Investor Conference Participation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\",\"datePublished\":\"2023-08-31T11:09:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-announces-september-investor-conference-participation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology Announces September Investor Conference Participation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology Announces September Investor Conference Participation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology Announces September Investor Conference Participation - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference Format: Fireside chat with analyst, Swayampakula Ramakanth Date: Monday, September 11Time: 2:30 PM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here 2023 Cantor Global Healthcare Conference Format: Fireside chat with analyst, Li WatsekDate: Tuesday, September 26Time: 9:10 AM Eastern TimeLocation: New York, NY Webcast link: Available\u00a0here The live webcasts for the H.C. Wainwright and Cantor fireside chats can be accessed by visiting the Investors section of ALX Oncology\u2019s website at www.alxoncology.com &hellip; Continue reading \"ALX Oncology Announces September Investor Conference Participation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-31T11:09:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology Announces September Investor Conference Participation","datePublished":"2023-08-31T11:09:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/"},"wordCount":479,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/","name":"ALX Oncology Announces September Investor Conference Participation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=","datePublished":"2023-08-31T11:09:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDEyMiM1NzkxNDc2IzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-announces-september-investor-conference-participation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology Announces September Investor Conference Participation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781242"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781242\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}